Skip to main content

Advertisement

SpringerLink
Log in

Fast clearance of anti-TNFα agents unrelated to antidrug antibodies: a case report

  • Letter to the Editor
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ben-Horin S, Kopylov U, Chowers Y (2014) Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 13(1):24–30. https://doi.org/10.1016/j.autrev.2013.06.002

    Article  CAS  PubMed  Google Scholar 

  2. Gisbert JP, Marín AC, McNicholl AG, Chaparro M (2015) Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther 41(7):613–623. https://doi.org/10.1111/apt.13083

    Article  CAS  PubMed  Google Scholar 

  3. Papamichael K, Cheifetz AS (2019) Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug? Curr Opin Gastroenterol 35(4):302–310. https://doi.org/10.1097/MOG.0000000000000536

    Article  PubMed  PubMed Central  Google Scholar 

  4. Regazzi M, Golay J, Molinaro M (2020) Monoclonal antibody monitoring: clinically relevant aspects, a systematic critical review. Ther Drug Monit 42(1):45–56. https://doi.org/10.1097/FTD.0000000000000681

    Article  PubMed  Google Scholar 

  5. Jongsma MME, Winter DA, Huynh HQ, Norsa L, Hussey S, Kolho KL, Bronsky J, Assa A, Cohen S, Lev-Tzion R, Van Biervliet S, Rizopoulos D, de Meij TGJ, Shouval DS, Wine E, Wolters VM, Martinez-Vinson C, de Ridder L, Paediatric IBD Porto Group of ESPGHAN (2020) Infliximab in young paediatric IBD patients: it is all about the dosing. Eur J Pediatr 179(12):1935–1944. https://doi.org/10.1007/s00431-020-03750-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, Simoens S, Rutgeerts P, Gils A, Vermeire S (2015) Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 148(7):1320–9.e3. https://doi.org/10.1053/j.gastro.2015.02.031

    Article  CAS  PubMed  Google Scholar 

  7. Frymoyer A, Piester TL, Park KT (2016) Infliximab dosing strategies and predicted trough exposure in children with Crohn disease. J Pediatr Gastroenterol Nutr 62(5):723–727. https://doi.org/10.1097/MPG.0000000000001123.PMID:26890885;PMCID:PMC4842177

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Assa A, Matar M, Turner D, Broide E, Weiss B, Ledder O, Guz-Mark A, Rinawi F, Cohen S, Topf-Olivestone C, Shaoul R, Yerushalmi B, Shamir R (2019) Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn’s disease compared with reactive monitoring. Gastroenterology 157(4):985–996.e2. https://doi.org/10.1053/j.gastro.2019.06.003

    Article  CAS  PubMed  Google Scholar 

  9. Roblin X, Marotte H, Rinaudo M, Del Tedesco E, Moreau A, Phelip JM, Genin C, Peyrin-Biroulet L, Paul S (2014) Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 12(1):80–84.e2. https://doi.org/10.1016/j.cgh.2013.07.010

    Article  CAS  PubMed  Google Scholar 

  10. Song GG, Seo YH, Kim JH, Choi SJ, Ji JD, Lee YH (2015) Association between TNF-α (-308 A/G, -238 A/G, -857 C/T) polymorphisms and responsiveness to TNF-α blockers in spondyloarthropathy, psoriasis and Crohn’s disease: a meta-analysis. Pharmacogenomics 16(12):1427–1437. https://doi.org/10.2217/pgs.15.90

    Article  CAS  PubMed  Google Scholar 

  11. Qasem A, Ramesh S, Naser SA (2019) Genetic polymorphisms in tumour necrosis factor receptors (TNFRSF1A/1B) illustrate differential treatment response to TNFα inhibitors in patients with Crohn’s disease. BMJ Open Gastroenterol 6(1):e000246. https://doi.org/10.1136/bmjgast-2018-000246

    Article  PubMed  PubMed Central  Google Scholar 

  12. Seitz M, Wirthmüller U, Möller B, Villiger PM (2007) The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 46(1):93–96. https://doi.org/10.1093/rheumatology/kel175

    Article  CAS  Google Scholar 

  13. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D (2003) Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 48(7):1849–1852. https://doi.org/10.1002/art.11168

    Article  CAS  PubMed  Google Scholar 

  14. Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, Mahieu P, Malaise M, De Groote D, Louis R, Belaiche J (1998) Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 113(3):401–406. https://doi.org/10.1046/j.1365-2249.1998.00662.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unit of Clinical Pharmacology, L. Sacco University Hospital, Milan, Italy

    Stefania Cheli, Valeria Cozzi & Dario Cattaneo

  2. Pediatric Hepatology, Gastroenterology and Transplantation Unit, ASST Papa Giovanni XXIII, Bergamo, Italy

    Lorenzo Norsa

  3. Pediatrics Division, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

    Costantino De Giacomo & Chiara Moretti

  4. Unit of Clinical Pharmacology, Dept Biomedical and Clinical Sciences, L. Sacco University Hospital, University of Milan, Milan, Italy

    Emilio Clementi

  5. Scientific Institute IRCCS Eugenio Medea, Bosisio Parini, Lecco, Italy

    Emilio Clementi

  6. Unit of Clinical Pharmacology, ASST Fatebenefratelli, Sacco University Hospital, Milan, Italy

    Stefania Cheli

Authors
  1. Stefania Cheli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valeria Cozzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dario Cattaneo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lorenzo Norsa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Costantino De Giacomo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Emilio Clementi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chiara Moretti
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Stefania Cheli conceived and designed the analysis. S.C verified the analytical methods and performed the analysis. S.C. took the lead in writing the manuscript. Valeria Cozzi contributed to sample preparation and to perform the experiments. Dario Cattaneo involved in the design, analysis of the results, and to the writing of the manuscript. Lorenzo Norsa collaborated in the clinical patient management. L.N contributed to describe the patient’s medical presentation and treatments. Costantino De Giacomo participated in planning and supervised the work. Emilio Clementi directed the project and aided in interpreting the results and worked on the manuscript. Chiara Moretti involved in clinical management of the patient. C.M. helped shape the research, analysis, and manuscript. All authors provided critical feedback and helped shape the research, analysis, and manuscript.

Corresponding author

Correspondence to Stefania Cheli.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 444 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cheli, S., Cozzi, V., Cattaneo, D. et al. Fast clearance of anti-TNFα agents unrelated to antidrug antibodies: a case report. Eur J Clin Pharmacol 78, 891–893 (2022). https://doi.org/10.1007/s00228-022-03294-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-022-03294-2

Search

Navigation